Clinical DevelopmentLast reviewed April 2026

Umbrella Trial(Umbrella Trial)

A clinical trial design that tests multiple investigational therapies against a single disease, typically with biomarker-driven patient assignment to treatment arms.

Usage Examples

The umbrella trial assigned lung cancer patients to five investigational arms based on genomic profiling.
A shared control arm in the umbrella design reduced overall enrollment requirements by 30%.

What is Umbrella Trial?

An umbrella trial evaluates multiple investigational therapies targeting one disease, typically with patients assigned to treatment arms based on molecular or biomarker profiling. The design is especially valuable in oncology where one cancer type has multiple targetable mutations and matching each patient to the appropriate targeted therapy is operationally challenging in sequential trials.

Umbrella trials use a master protocol with shared infrastructure: common patient screening, centralized biomarker testing, shared operational vendors, and often a shared control arm. Individual treatment arms can open and close based on emerging evidence without disrupting the overall trial. Examples include LUNG-MAP (advanced squamous cell lung cancer) and FOCUS4 (colorectal cancer). Biomarker-negative patients may be assigned to standard-of-care control or off-target investigational arms.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH E9, FDA GUIDANCE MASTER PROTOCOLS.

FDAEMAPMDA

When This Matters

The umbrella trial assigned lung cancer patients to five investigational arms based on genomic profiling.
A shared control arm in the umbrella design reduced overall enrollment requirements by 30%.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

ICH E9FDA GUIDANCE MASTER PROTOCOLS

Frequently Asked Questions

Umbrella: multiple therapies tested against one disease, often biomarker-stratified. Basket: one therapy tested across multiple diseases sharing a target. Umbrella focuses on matching therapies to patient biology within a disease; basket focuses on cross-disease activity of one therapy.

Typically yes for biomarker-stratified assignment. Central biomarker testing ensures consistent patient assignment across sites. Companion diagnostics may receive separate FDA review alongside or after therapeutic approval.

Yes, through protocol amendments. Adaptive umbrella designs allow new investigational arms to open and unsuccessful arms to close based on interim analyses. Regulatory coordination through Type B meetings is recommended for significant design changes.